Metotrexato Mylan

Methotrexate, the active ingredient in Metotrexato Mylan, is an antimetabolite presented as a parenteral solution for subcutaneous use. It treats autoimmune disorders such as rheumatoid arthritis and psoriasis, and is also employed in oncology protocols for acute lymphoblastic leukemia.

GNH USA supplies Metotrexato Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Methotrexate is used in several disease families where it modulates immune activity and cell proliferation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication as part of chemotherapy regimens.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general feeling of tiredness. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: transient hepatic enzyme rise. - Low blood counts: mild leukopenia or anemia.

Serious or Rare Side Effects: - Severe liver toxicity: risk of fibrosis or cirrhosis. - Pulmonary fibrosis: interstitial lung disease. - Bone marrow suppression: severe pancytopenia. - Renal impairment: acute kidney injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome.

When prescribing methotrexate, clinicians should observe several safety measures to minimise risk.

- Baseline testing: obtain liver function, renal function and complete blood count before initiation. - Monitoring: repeat laboratory tests regularly to detect hepatotoxicity or cytopenias. - Contraindications: avoid in patients with severe hepatic disease or active infections. - Pregnancy: discontinue and avoid use in women who are pregnant or may become pregnant. - Drug interactions: review concomitant medications that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several agents that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can raise methotrexate serum levels and risk renal toxicity. - Proton pump inhibitors: may increase methotrexate exposure and hepatic toxicity. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk. - Azathioprine or other immunosuppressants: additive myelosuppression. - Penicillins (high‑dose): may reduce renal clearance of methotrexate.